Table 4. Estimated in vivo % residual DNA-dependent polymerization for distinct mutants and drug combinations.

	wt	Q151M	M184V	K65R	M184V/K65R
TFV-DP	4.16–24.11	9.20–42.55	3.32–20.05	19.11–63.34	8.72–41.14
AZT-TP	29.47–80.69	-	-	-	-
d4T-TP	2.08–25.95	-	7.44–56.97	-	-
FTC-TP	2.07–21.45	1.24–14.00	-	21.28–77.76	47.37–92.09
3TC-TP	1.54–4.95	0.86–2.81	51.22–77.71	12.29–31.77	86.19–95.40
CBV-TP	7.63–14.18	82.27–90.27	45.49–62.53	-	-
FTC-TP	1.39–12.69	1.11–11.75	-	11.02–53.12	7.80–39.22
+TFV-DP
d4T-TP	0.91–4.40	-	7.01–49.20	-
+3TC-TP
CBV-TP	1.33–3.89	0.87–2.84	32.20–53.53	-	-
+3TC-TP
CBV-TP	1.27–3.81	-	-	-	-
+3TC-TP
+AZT-TP
fitness	100	100	46	38	30

In vivo concentration ranges were 3TC-TP = 12.2–40.5; FTC-TP = 1.5–19.4; TFV-DP = 0.16–1.17; CBV-TP = 0.44–0.88; d4T-TP = 0.034–0.56; and AZT-TP = 0.0056–0.056 respectively [56], [71], [73]–[75], assuming an average cell volume of for resting T-cells [72].